Childhood survivors of high-risk neuroblastoma show signs of
immune recovery and not immunosenescence

J 2020

Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence

LÁZNIČKOVÁ, Petra, Tomáš KEPÁK, Marcela HORTOVÁ KOHOUTKOVÁ, Luděk HORVÁTH, Kateřina SHEARDOVÁ et. al.

Basic information

Original name

Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence

Authors

LÁZNIČKOVÁ, Petra (203 Czech Republic, belonging to the institution), Tomáš KEPÁK (203 Czech Republic), Marcela HORTOVÁ KOHOUTKOVÁ (203 Czech Republic), Luděk HORVÁTH (203 Czech Republic), Kateřina SHEARDOVÁ (203 Czech Republic), Rafał MARCINIAK (203 Czech Republic), Carmine VACCA (380 Italy), Michaela SIKLOVA (203 Czech Republic), Teresa ZELANTE (380 Italy), Lenka ROSSMEISLOVA (203 Czech Republic), Zdenka KŘENOVÁ (203 Czech Republic), Jaroslav ŠTĚRBA (203 Czech Republic), Kamila BENDICKOVA (203 Czech Republic) and Jan FRIČ (203 Czech Republic, guarantor)

Edition

EUROPEAN JOURNAL OF IMMUNOLOGY, HOBOKEN, WILEY, 2020, 0014-2980

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.532

RIV identification code

RIV/00216224:14110/20:00116320

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/eji.202048541

UT WoS

000560133400001

Keywords in English

adverse late effects; childhood; immune recovery; immunosenescence; neuroblastoma

Abstract

V originále

Neuroblastoma survivors show signs of immunosenescence early after therapy in CD8(+)T cell compartment and elevated plasma TNF-alpha but in later follow-up immune recovery comes into play. Whether the recovery phenotype is long lasting or transient remains to be elucidated, however, late adverse effects often occur in childhood cancer survivors.

Links

MUNI/A/1409/2019, interní kód MU

Name: Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medicine" a "N-of-1 clinical trials"

Investor: Masaryk University, Category A

Citovat

LÁZNIČKOVÁ, Petra, Tomáš KEPÁK, Marcela HORTOVÁ KOHOUTKOVÁ, Luděk HORVÁTH, Kateřina SHEARDOVÁ, Rafał MARCINIAK, Carmine VACCA, Michaela SIKLOVA, Teresa ZELANTE, Lenka ROSSMEISLOVA, Zdenka KŘENOVÁ, Jaroslav ŠTĚRBA, Kamila BENDICKOVA and Jan FRIČ. Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence. EUROPEAN JOURNAL OF IMMUNOLOGY. HOBOKEN: WILEY, 2020, vol. 50, No 12, p. 2092-2094. ISSN 0014-2980. Available from: https://dx.doi.org/10.1002/eji.202048541.

@article{1676816,
   author = {Lázničková, Petra and Kepák, Tomáš and Hortová Kohoutková, Marcela and Horváth, Luděk and Sheardová, Kateřina and Marciniak, Rafał and Vacca, Carmine and Siklova, Michaela and Zelante, Teresa and Rossmeislova, Lenka and Křenová, Zdenka and Štěrba, Jaroslav and Bendickova, Kamila and Frič, Jan},
   article_location = {HOBOKEN},
   article_number = {12},
   doi = {http://dx.doi.org/10.1002/eji.202048541},
   keywords = {adverse late effects; childhood; immune recovery; immunosenescence; neuroblastoma},
   language = {eng},
   issn = {0014-2980},
   journal = {EUROPEAN JOURNAL OF IMMUNOLOGY},
   title = {Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence},
   url = {https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048541},
   volume = {50},
   year = {2020}
}

TY  - JOUR
ID  - 1676816
AU  - Lázničková, Petra - Kepák, Tomáš - Hortová Kohoutková, Marcela - Horváth, Luděk - Sheardová, Kateřina - Marciniak, Rafał - Vacca, Carmine - Siklova, Michaela - Zelante, Teresa - Rossmeislova, Lenka - Křenová, Zdenka - Štěrba, Jaroslav - Bendickova, Kamila - Frič, Jan
PY  - 2020
TI  - Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence
JF  - EUROPEAN JOURNAL OF IMMUNOLOGY
VL  - 50
IS  - 12
SP  - 2092-2094
EP  - 2092-2094
PB  - WILEY
SN  - 00142980
KW  - adverse late effects
KW  - childhood
KW  - immune recovery
KW  - immunosenescence
KW  - neuroblastoma
UR  - https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048541
L2  - https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048541
N2  - Neuroblastoma survivors show signs of immunosenescence early after therapy in CD8(+)T cell compartment and elevated plasma TNF-alpha but in later follow-up immune recovery comes into play. Whether the recovery phenotype is long lasting or transient remains to be elucidated, however, late adverse effects often occur in childhood cancer survivors.
ER  -

LÁZNIČKOVÁ, Petra, Tomáš KEPÁK, Marcela HORTOVÁ KOHOUTKOVÁ, Luděk HORVÁTH, Kateřina SHEARDOVÁ, Rafał MARCINIAK, Carmine VACCA, Michaela SIKLOVA, Teresa ZELANTE, Lenka ROSSMEISLOVA, Zdenka KŘENOVÁ, Jaroslav ŠTĚRBA, Kamila BENDICKOVA and Jan FRIČ. Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence. \textit{EUROPEAN JOURNAL OF IMMUNOLOGY}. HOBOKEN: WILEY, 2020, vol.~50, No~12, p.~2092-2094. ISSN~0014-2980. Available from: https://dx.doi.org/10.1002/eji.202048541.

Detailed Information on Publication Record